Enanta
Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial
Enanta Pharmaceuticals; RSV; zelicapavir; Phase IIb trial; primary endpoint miss; secondary endpoints; clinical trials; FDA Fast Track; elderly; COPD; congestive heart failure; hospitalization rates; future development
Enanta Pharmaceuticals Achieves Breakthrough in RSV Treatment with EDP-323, Demonstrating Significant Reductions in Viral Load and Symptoms
Enanta Pharmaceuticals, EDP-323, Respiratory Syncytial Virus (RSV), Antiviral Treatment, Phase 2a Human Challenge Study, Viral Load Reduction, Symptom Alleviation